Product
Afuresertib
Aliases
LAE002
3 clinical trials
8 indications
Indication
Platinum-resistant Ovarian CancerIndication
Solid TumorIndication
NSCLCIndication
Cervical CancerIndication
Endometrial CancerIndication
Esophageal cancerIndication
Breast CancerClinical trial
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-07-31
Clinical trial
A Phase I/II Dose-Escalation and Efficacy/Safety Study of Afuresertib Plus Sintilimab Plus Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 TreatmentStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care TherapiesStatus: Active (not recruiting), Estimated PCD: 2023-04-27